Core Viewpoint - The company, Kehua Bio-Engineering (002022), is leveraging its immune technology platform to develop tumor marker detection reagents for early screening and auxiliary diagnosis of cancers such as liver, stomach, and lung cancers [1] Group 1: Product Development - The company has developed tumor marker detection reagents that can be used in conjunction with its universal detection instruments for early cancer screening and auxiliary diagnosis [1] - A subsidiary, Tianlong, has developed products based on fluorescence PCR technology that assist in cancer screening, including HPV detection kits for cervical cancer and EB virus detection kits for nasopharyngeal cancer [1]